Mylab Discovery Solutions announced the appointment of Rajesh Patel as the Executive Director – in-vitro diagnostics (IVD) business. In his role, he will be responsible for spearheading the IVD testing equipment and reagent business at Mylab by setting up production units, overseeing the related research and development and the launch of the products across the domestic and overseas markets.

Rajesh brings over 30 years of deep and diverse experience in the area of Sales, Marketing and Business Development in various healthcare segments including Pharmaceuticals, Clinical Research Organizations, Clinical Trials and IVD/ Medical Devices. He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation.

Speaking on Rajesh’s appointment, Hasmukh Rawal, Managing Director of Mylab, said, “I am delighted that Rajesh has joined us in this essential development phase of the company. His unparalleled industry and leadership experience in the field of diagnostics and the pharmaceutical industry will be very valuable to us and will help our IVD business to scale new heights. At Mylab, we are continuously striving to make diagnostics affordable and accessible to all by introducing innovative technology platforms for labs and bringing testing closer to the patient.”

“In the relatively short term, Mylab has set new benchmarks in the diagnostics industry with its pioneering and innovative products. I’m extremely excited to join the team at a key stage in the company’s growth and play a part in helping the company realize its significant potential.”, said Rajesh Patel, Executive Director, Mylab.

Rajesh has held positions of increasing responsibilities in several reputed companies including Pfizer, Meril Diagnostics, Agappe Diagnostics, Transasia Bio-Medicals and Quest Diagnostics. Rajesh was closely involved in building the business right from conceptualisation to planning and then to implementation. He also has immense knowledge of Biochemistry, Haematology, Molecular Biology, Immunology, Critical care, Coagulation and general laboratory consumables.

Mylab has earmarked Rs 100 crore for building the IVD business and aims to place its products in 1000 labs within the first 6 months from the time of launch and acquire a market share of 10% by the end of 2024 with its reach to more than 20000 labs.